Second Sight Medical Products (NASDAQ:EYES) announced its quarterly earnings results on Monday. The medical device company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.16), Fidelity Earnings reports. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 183.76%.
Shares of NASDAQ:EYES opened at $0.97 on Tuesday. The firm has a market cap of $15.19 million, a price-to-earnings ratio of -0.41 and a beta of 2.41. Second Sight Medical Products has a 12 month low of $0.71 and a 12 month high of $8.96. The company’s fifty day simple moving average is $1.04 and its 200 day simple moving average is $2.50. The company has a quick ratio of 1.74, a current ratio of 1.88 and a debt-to-equity ratio of 0.33.
EYES has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $2.50 target price on shares of Second Sight Medical Products in a report on Friday, March 20th. ValuEngine raised Second Sight Medical Products from a “hold” rating to a “buy” rating in a research report on Thursday, April 9th. Finally, Zacks Investment Research lowered Second Sight Medical Products from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th.
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Recommended Story: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.